Bejar et al identified somatic mutations associated with a poor outcome for patients with the myelodysplastic syndrome undergoing hematopoietic stem cell transplantation (HSCT). These can help to identify a patient who may or may not benefit from the procedure. The authors are from the University of California at San Diego, Dana Farber Cancer Institute, Brigham and Women's Hospital and Broad Institute (Cambridge).
